Advances in neurology

Colin R Kennedy

This is 'the decade of the brain'. Knowledge of mechanisms underlying neurological disease has advanced rapidly using many new investigative tools particularly in cellular biology and molecular genetics. Simultaneously, clinical neurological practice has changed substantially with new imaging techniques and a wider range of therapeutic options particularly in the management of epilepsy.

Molecular genetics in neurological disorders

LINKAGE ANALYSIS

Inherited neurological diseases, although individually rare, have a collective incidence of over 58 per 100 000 population (one per 1700). The use of restriction fragment length polymorphisms to construct genetic linkage maps for the localisation of disease genes was first suggested 15 years ago. This depends on chromosomal localisation of the disorder rather than isolating the individual gene. Successful application depends on correct diagnosis, heterozygosity for the marker polymorphisms (an 'informative' family), and genetic homogeneity—a single gene locus for the clinical phenotype. The technique is useful for genetic counselling of families, particularly those affected by neuromuscular disorders including Emery-Dreifuss, limb-girdle muscular dystrophies, and spinal muscular atrophy of all types.

GENE IDENTIFICATION

In some disorders, DNA samples from affected individuals can be tested for alterations of the gene, including point mutations, insertions, and deletions. Unlike linkage analysis, this can be applied to an individual patient without the need for family studies. The proportion of cases in which a mutation can be identified varies widely: for example, 20% of cases with neurofibromatosis type 1 and 100% of those with hereditary motor sensory neuropathy—Charcot-Marie-Tooth disease—types 1A and 1B. There is a clinical role for this type of testing in at least 14 neuromuscular disorders and the number is rapidly increasing. Duchenne and Becker muscular dystrophies are the commonest with identifiable mutations in about 70%. The more severe Duchenne phenotype usually involves deletions that disrupt the translational reading frame of the mRNA triplet codons for the gene product, dystrophin. Although DNA testing alone cannot be used reliably to predict phenotype, characterisation of dystrophin allows alternative strategies for diagnosis when DNA testing is unhelpful or when questions remain in a particular family about the phenotype. DNA testing also plays an invaluable part in carrier detection and prenatal diagnosis.

These advances have improved diagnosis and understanding of mechanisms in Duchenne muscular dystrophy and other muscular dystrophies but have not yet led to useful treatment; gene transfer therapy is a future prospect that awaits development of a viable mode of gene delivery.

A new class of mutation, the trinucleotide repeat, has been identified and found to underlie the fragile X syndrome, myotonic dystrophy, Huntington's disease, and at least four other degenerative neurological diseases. In these diseases, the number of repeats of a base triplet sequence is increased.

The expanded sequence is unstable in size and the phenomenon of anticipation occurs: age of onset is lowered and clinical manifestations or phenotype become more severe over successive generations because of progressive increase in size of the repeated segment. Parent of origin effects are marked in the transmission of such 'dynamic' mutations; this helps explain the occurrence of the congenital form of myotonic dystrophy only in children of affected mothers (fig 1); of the juvenile form of Huntington's disease in the children of affected fathers; and of greater anticipation in the children of affected mothers in fragile X.

Fragile X and myotonic dystrophy are multisystem disorders associated with large expansions of repeats and their pathological effect may be due to shutting off gene transcription. Huntington's disease and the other neurodegenerative disorders are caused by smaller expansions of CAG repeats within the protein coding portion of the gene. CAG repeats encode polyglutamine, which has recently been shown to be translated into protein in these disorders and may have its effect by a toxic effect of the polyglutamine perhaps by influ-

Child Health
Directorate,
Southampton General
Hospital, Tremona
Road, Southampton
SO16 6YD

Correspondence to:
Dr Kennedy.
Figure 1  Trinucleotide expansion in myotonic dystrophy. The pedigree shows a family with a son (filled square) presenting with myotonic dystrophy (MD). Using a DNA probe specific for the MD gene, the two alleles of the gene are shown below each member of the family. The normal pattern is of two bands, one of 9 kb and one of 10 kb, as shown for the sister and father of the proband. The mother and the proband both have an expansion (CTG) within the gene. In the mother the expansion is slight. This implies that she has MD but symptoms are likely to be mild and of late onset. The proband has a larger expansion shown by the upper and fainter of his two bands, which is substantially larger than 10 kb. The MD gene has expanded during transmission from mother to son.

ence programmed cell death (see below). Trinucleotide repeats yet to be identified may also underlie a number of other clinically variable neurological diseases.

Neuronal death and cerebral protection

APOPTOSIS: PROGRAMMED CELL DEATH

Loss of neurones is a normal part of central nervous system development in which developmental switches, perhaps related to failure to establish appropriate trophic connections, trigger cell death. Only a proportion of sensory neurons, for example, receive enough nerve growth factor, released by their target cells, to survive. Similarly, developing glial cells require signals such as platelet derived and insulin-like growth factors from other cells to survive (fig 2). Neuronal death is also an important part of many neurological diseases whether inflammatory, traumatic, metabolic, or respiratory (hypoxic, ischaemic). Many experimental studies suggest that asphyxial insults initiate cascades of events for a time after the insult (fig 2) and also that intervention can rescue neurones.

Gluckman and Williams have divided the process into five time periods. Firstly, the pre-insult period with state of maturity, metabolic status, and growth retardation influencing the effect of any subsequent insult. Second, there is the insult phase with some "primary neuronal death". Energy failure leads to widespread metabolic disruption, sodium and chloride influx, and accumulation of neurotransmitters and intracellular calcium. The latter may lead to inappropriate activation of normally suppressed programmed cell death (apoptosis).

Thirdly, a 10 to 30 minute reperfusion phase is associated with release of cytotoxins including free radicals, prostanoids, and nitric oxide. Cellular energy is restored but neuronal activity remains depressed for some hours perhaps because of inhibitory neuromodulators such as adenosine, opioids, and y-aminobutyric acid. Fourthly, six to 12 hours after the insult there is a further period of oedema and metabolic disruption lasting 12 to 48 hours. This is associated with neuronal hyperexcitability and the transformation of microglia into activated macrophages followed by further release of nitric oxide and glutamate. This phagocytic activation may be central to secondary neuronal cell death occurring at this time. Finally at 36 to 72 hours neurotrophic factors are induced, such as insulin-like growth factor, fibroblast growth factor, and calcitonin gene related peptide; these appear to be neuroprotective (fig 2).

INTERVENTION STUDIES AND CLINICAL APPLICATION

Blockade of glutamate receptors, including the much studied N-methyl-D-aspartate subtype, reduces damage in some experimental situations. The pattern of cellular events differs between focal and global insults, according to the duration and timing of the asphyxial event and maturity of the brain. These variables influence the effect of interventions in experimental studies of asphyxia.

These experimental observations are relevant to clinical situations. Magnetic resonance spectroscopy studies in human infants have shown that acute asphyxia is often associated with a transient reduction in high energy substrates, followed several hours later by a prolonged fall associated with clinical encephalopathy. These observations support the concept of neuronal damage occurring after a delay of several hours after asphyxia. Raised

Figure 2  Programmed cell death. Electron micrographs (reproduced by permission of Professor M Raff) of oligodendrocyte precursor cells cultured with (upper micrograph) or without (lower micrograph) insulin, a survival factor. Without insulin, cells die as part of normal development through a process of programmed cell death or apoptosis. Programmed cell death can also be activated by asphyxia or other metabolic insults through a series of steps (see text) summarised in the diagram.
cerebrospinal fluid glutamate concentrations in this clinical situation also support postulated excitotoxicity.14 Experimental observations also link excitotoxicity to the prenatal induction of apparently neurodevelopmental disorders such as polymicrogyria,15 to postnatal insults including hypothermic circulatory arrest and tuberculous meningitis,16 and to cell death in neurodegenerative diseases (for example Parkinson’s and Huntington’s diseases).13 Careful clinical application of these findings may improve the outcome of a variety of neurological insults in future.

**Neuroimaging**

The replacement of pneumoencephalography by computed tomography in the early 1970s led to a revolution in neurological and neurosurgical practice. Myelography was also improved by the introduction of safer water soluble dye as was angiography by digital subtraction angiography.

A revolution of comparable magnitude has begun with the arrival of magnetic resonance imaging (MRI) and the more recent functional magnetic resonance imaging (fMRI), which have the advantage of avoiding ionising radiation. The basic principles and clinical place of these techniques alongside computed tomography and the radionuclide techniques of positron emission tomography (PET) and single photon emission tomography (SPECT) are the subject of several recent reviews.17-25 All methods of obtaining a magnetic resonance signal use radiofrequency pulses to perturb magnetisation in the patient's body water induced by a strong external magnetic field. The slow but robust ‘spin echo’ techniques are being replaced by faster ‘gradient echo’ sequences which can be used either to improve localisation or to decrease acquisition time: slices can be acquired in a third of a second and individual scans are repeatable if degraded by patient movement. In functional imaging, echoplanar imaging employs either induction decay over a fraction of a second or a rapid succession of excitation pulses. This explores in detail changes in signals over time likely to result from changing neuronal function.

**CLINICAL APPLICATION**

MRI, but not yet fMRI, has become an essential tool in paediatric neurological practice. It has helped to define specific clinical syndromes associated with defects of neuronal migration dating from early fetal life.24-28 It has shown abnormalities, rarely visible on computed tomography, underlying common clinical problems such as global developmental delay and microcephaly (fig 3). MRI has already established its superiority over computed tomography in detecting abnormalities in the spine or near the skull base particularly the posterior fossa.9 31 It has also played an important part in managing epilepsy (see below).22-25 28 Its role in the diagnosis of neurologically determined birth defects (figs 3–5) will continue to expand as technology is updated leading to more child friendly MRI units and better images. Age specific limits of normality have been defined32 and are addressed in the latest neuroradiology reference texts but will need to be refined as the technology to measure volumes and gyral patterns tempts enthusiasts into the zone of incidental findings.

The future role of fMRI in clinical practice is yet to be defined. Functional imaging is likely to play an important part in the assessment of
neuroprotective agents in hypoxia, ischaemia, and cerebrovascular disease but fMRI has yet to displace PET or SPECT either in this field or in assessing movement disorders or presurgical evaluation of intractable epilepsy.\(^\text{20–23}\)

### Epilepsy

Four areas of significant advance have combined to produce a substantial improvement in the management of suspected epilepsy. Firstly, there have been advances in diagnostic precision. These include distinguishing epilepsy from other paroxysmal events,\(^\text{31–34}\) and identifying certain specific syndromes\(^\text{35–37}\) based on seizure type(s), age, associated neurodevelopmental features, family history, and electroencephalography.

Secondly, advances in antiepileptic drug treatment have decreased the number of children in whom seizures are either intractable or controlled at the cost of unacceptable adverse effects (table 1).\(^\text{38–40}\) For example for partial and secondarily generalised epilepsies,\(^\text{41}\) vigabatrin, lamotrigine, gabapentin, and topiramate; for infantile spasms,\(^\text{42}\) vigabatrin; and for Lennox–Gastaut syndrome and generalised epilepsies,\(^\text{43}\) lamotrigine, have all been shown to be effective, sometimes dramatically in individual patients. This has been accompanied by a resurgence of interest in remediating subclinical and cognitive manifestations of epilepsy.\(^\text{44}\)

Thirdly, advances in neuroimaging have helped select those who may benefit from seizure surgery (figs 4–6).\(^\text{21–23, 28}\) This includes patients with (1) temporal lobe epilepsy with hippocampal sclerosis or alien tissue (fig 6), (2) extratemporal epilepsy with alien tissue in a resectable site, (3) epilepsy with infantile or childhood hemiplegia (fig 4), (4) Rasmussen’s encephalitis, (5) drop attacks, and (6) acquired auditory aphasia (Landau–Kleffner syndrome).\(^\text{45}\)

---

**Table 1 Drug treatment according to seizure type**

<table>
<thead>
<tr>
<th>Seizure Type</th>
<th>First choice</th>
<th>Second choice</th>
<th>Third choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial</td>
<td>Carbamazepine</td>
<td>Vigabatrin</td>
<td>Sodium valproate</td>
</tr>
<tr>
<td>Generalised</td>
<td>Sodium valproate</td>
<td>Lamotrigine</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>tonic-clonic</td>
<td>Ethosuximide</td>
<td>Sodium valproate</td>
<td>Lamotrigine</td>
</tr>
<tr>
<td>Absence</td>
<td>Sodium valproate</td>
<td>Lamotrigine</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>Myoclonic</td>
<td>Sodium valproate</td>
<td>Lamotrigine</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>Atonic</td>
<td>Lamotrigine</td>
<td>Sodium valproate</td>
<td>Clonazepam</td>
</tr>
</tbody>
</table>

* The relative merits of anticonvulsants in an individual child will be influenced by factors other than seizure type including seizure syndrome (if identifiable), presence of learning disability, behavioural problems, etc.
† Only for absences associated with bilaterally synchronous 3 per second spike and wave on electroencephalography, otherwise known as petit mal.
Fourthly, the need to disseminate these advances to bring about changes in epilepsy management has led to examination of the 'model of care'. The Epilepsy Task Force has circulated to purchasers A Guide to Good Practice. There are an increasing number of specialist epilepsy nurses, more written information for families is available, and there is a greater awareness of the central importance of patient and family perceptions of the condition.

Deficiencies in integrating epilepsy care remain. There are similar deficiencies in the care of children with other neurological disorders because of limited resources within individual districts, haphazard patterns of onward referral, and poor coordination between medical and other sectors. Nevertheless, the last five years have seen the consolidation of child development centres and increasing cooperation between the agencies involved in caring for children with neurological disorders. If the promise of molecular genetics and of neuroscience discussed above is fulfilled, further improvements in the model of care will be driven by an increase in the options for effective treatment.

Grateful thanks to Dr John Miller, Professor Martin Raff, and Dr Karen Temple for their help with the figures.
